Blood test may track ovarian cancer treatment response
Part of Cancer, Women’s health & pregnancy clinical trials.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ovarian cancer (or cancer of the fallopian tube or the lining of the abdomen) for the first time and received initial treatment
- Your cancer diagnosis was confirmed by pathology as epithelial type
- Your cancer is stage II, III, or IV, and surgery is planned after evaluation
- You are 18 years or older and can understand the study and sign consent
- You plan to use standard first-line targeted treatment drugs that your care team recommends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study is testing a new blood test that looks for DNA changes to help detect ovarian cancer earlier. You would give a blood sample before your planned surgery or biopsy, and researchers will compare the test results with your pathology report to see how accurate it is.
This study uses a simple blood test to look for tiny amounts of cancer DNA after you've finished your first treatment. It aims to see if this test can predict whether the cancer might come back, which could help guide future care.
This study checks whether a special blood test (circulating tumor DNA) can help find ovarian cancer when it’s suspected. It may help doctors diagnose more accurately and sooner, so the right treatment can start sooner.
This study is testing whether a simple blood test can predict the risk of ovarian cancer coming back after treatment. It might help doctors decide who needs more aggressive therapy.
This study looks at blood samples from people with ovarian cancer to measure a marker called ctDNA (bits of tumor DNA in the blood). The goal is to see if changes in this marker before and after surgery can help predict or monitor the cancer.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.